By-health Co. Shows Improved Valuation Metrics Amid Strong Financial Performance

By-health Co., Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment that reflects a notable shift in its valuation metrics. The company has reported a valuation grade that has transitioned to a more favorable standing, indicating a fair assessment of its financial position. Key financial indicators reveal a P/E ratio of 28, alongside a Price to Book Value of 1.74. The company’s EV to EBIT stands at 17.44, while the EV to EBITDA is recorded at 13.99. Additionally, By-health Co. boasts a PEG ratio of 2.40 and a dividend yield of 3.11%. The latest Return on Capital Employed (ROCE) is 12.82%, and the Return on Equity (ROE) is at 6.14%, suggesting a balanced approach to capital utilization. The company has demonstrated positive financial performance over the last three quarters, with a net profit of CNY 401.27 million, reflecting a growth rate of 89.31%. Furthermore, raw material costs have decreased by 4.8% year-over-year, contributing to its robust cash position of CNY 12,265.47 million. This evaluation adjustment highlights By-health Co.'s solid market position and operational efficiency, reinforcing its standing in the competitive landscape of the pharmaceuticals and biotechnology industry. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.